Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Small Molecule as a Potential Treatment for Glaucoma
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1433
Glaucoma is a common cause of blindness in industrialized countries and is the most frequent cause of irreversible blindness worldwide. Since raised intraocular pressure (IOP) has been implicated...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Glaucoma is a common cause of blindness in industrialized countries and is the most frequent cause of irreversible blindness worldwide. Since raised intraocular pressure (IOP) has been implicated as the major risk factor, the main goal of all glaucoma therapies is to reduce IOP sufficiently to prevent continuous irreversible retinal cell damage. All the existing medications have local and systemic side effects, from eye burning to breathing difficulties.

Aims/Hypothesis

Therefore there is a clear need for a new generation of glaucoma drugs with a safer profile.

Results

Researchers at Prof. Steve Karlish's lab developed novel derivatives of Digoxin that can be topically applied to the eyes. The current technology is based on derivatives of Digoxin, an inhibitor of the Na-K-ATPase pump, which is critical for the production of the eye fluids. The novel derivatives of Digoxin present higher selectivity towards the alpha2 isoform of the Na-K-ATPase pump that is more prevalent in the eye epithelium. Importantly, this molecular specificity offers a well-tolerated safety profile. Overall, this technology offers an effective reduction in ocular hypertension, the major risk factor in glaucoma, with diminished local side effects.

Conclusion

Alpha2-selective inhibitors effectively reduce IOP, and are therefore suitable for treating glaucoma and other ocular hypertension-associated diseases.

Relevance/Opportunity

Please enquire quoting reference no. 1433 regarding licensing or codevelopment partnerships.
GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2015
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION